Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 5/20 | 0.51 |
| ▸ | PTPN13 | Q12923 | 2/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | TERT | O14746 | 4/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690773 | 1.00 | PTPRC (0.51) | PTPRCPTPN13P2RY12TDP1TERT | |
| SCHEMBL32690838 | 1.00 | PTPRC (0.51) | PTPRCPTPN13P2RY12TDP1TERT | |
| SCHEMBL32690721 | 0.99 | PTPRC (0.49) | PTPRCPTPN13P2RY12TDP1TERT | |
| SCHEMBL32690835 | 0.93 | P2RY12 (0.55) | PTPRCPTPN13P2RY12TDP1TERT | |
| SCHEMBL32690863 | 0.93 | P2RY12 (0.55) | PTPRCPTPN13P2RY12TDP1TERT | |
| SCHEMBL32690732 | 0.93 | P2RY12 (0.55) | PTPRCPTPN13P2RY12TDP1TERT | |
| SCHEMBL32690786 | 0.92 | P2RY12 (0.53) | PTPRCPTPN13P2RY12TDP1TERT | |
| SCHEMBL32690717 | 0.90 | P2RY12 (0.50) | P2RY12TERT | |
| SCHEMBL32690825 | 0.90 | P2RY12 (0.50) | P2RY12TERT | |
| SCHEMBL32690718 | 0.90 | P2RY12 (0.50) | P2RY12TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | NOX1, NOX4, CYBB | PTPRC 436/4885PTPN13 944/4885P2RY12 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.